Several survival markers for GBM have been identified so far, such as the patients’ age, initial clinical condition, extent of resection (EOR) and, particularly, molecular tumor characteristics such as methylation of the O6-methylguanin-DNA-methyltransferase (MGMT) gene promotor, or mutation of the isocitrate-dehydrogenase 1 (IDH1) gene [5]. Here, IDH1 is linked to glioblastoma.